March 3, 2026Open Access

VDAC1 and VDAC2 as prognostic biomarkers and therapeutic targets in hepatocellular carcinoma

Key Points

VDAC1 and VDAC2 are key biomarkers influencing outcomes in hepatocellular carcinoma.
Patients with specific expressions of VDAC1 and VDAC2 have different prognoses, indicating variable risks.
Assessment highlights genetic and immune interactions that affect the role of these biomarkers in therapy.
Further research may enable personalized treatments targeting VDAC1 and VDAC2 in hepatocellular carcinoma.

Abstract

VDAC1 and VDAC2 are prognostic biomarkers and therapeutic targets in HCC, with genetic and immune interactions jointly influencing outcomes, supporting their potential for patient risk stratification and targeted or immune-based therapies.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Deng et al. (Thu,) studied this question.

synapsesocial.com/papers/69a75d8ec6e9836116a27b47 https://doi.org/https://doi.org/10.21037/tcr-2025-1887

Bookmark

View Full Paper